Synopsis
Synopsis
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Apocard
2. Flcane
3. Flecadura
4. Flecainid Isis
5. Flecainid-isis
6. Flecainide
7. Flecainide Monoacetate
8. Flecainide Monoacetate, (+-)-isomer
9. Flecainide Monoacetate, (r)-isomer
10. Flecainide Monoacetate, (s)-isomer
11. Flecainide, (r)-isomer
12. Flecainide, (s)-isomer
13. Flecainide, 5-ho-n-(6-oxo)-derivative
14. Flecainide, 5-ho-n-(6-oxo)-derivative, (+-)-isomer
15. Flecatab
16. R818
17. Tambocor
1. 54143-56-5
2. Flecainide (acetate)
3. Tambocor
4. R-818
5. Flecainide Monoacetate
6. Flecainide Acetate Salt
7. R 818
8. 54143-56-5 (acetate)
9. N-(2-piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide Acetate
10. N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Monoacetate
11. Mls000069675
12. Chebi:5091
13. M8u465q1wq
14. Apocard
15. Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, Monoacetate
16. Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-,monoacetate
17. N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Monoacetate
18. Smr000058451
19. Acetic Acid;n-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
20. N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Acetate
21. Sr-01000000172
22. Einecs 258-997-5
23. Mfcd00214290
24. Unii-m8u465q1wq
25. Flecainidacetat
26. Tambocor (tn)
27. Flecainide Acetate [usan:usp:jan]
28. N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Monoacetate
29. Dsstox_cid_626
30. Opera_id_1587
31. 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidinylmethyl)benzamide Acetate
32. Cas-54143-56-5
33. Dsstox_rid_75700
34. Dsstox_gsid_20626
35. Mls001148177
36. Mls002222300
37. Schembl121583
38. Chembl1200822
39. Dtxsid8020626
40. Flecainide Acetate [jan]
41. Flecainide Acetate (jp17/usp)
42. Flecainide For System Suitability
43. Flecainide Acetate [usan]
44. Flecainide Acetate [vandf]
45. Hms1570c12
46. Hms2097c12
47. Hms2231e15
48. Hms3259f11
49. Hms3267n04
50. Hms3369m07
51. Hms3412d09
52. Hms3676d09
53. Hms3714c12
54. Flecainide Acetate [mart.]
55. 11a-hydroxyepoxyprogesterone
56. Bcp17825
57. Flecainide Acetate [usp-rs]
58. Flecainide Acetate [who-dd]
59. Tox21_200208
60. Akos015889993
61. N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide Acetate
62. Ccg-220735
63. Cs-1400
64. Nc00641
65. Sb19142
66. Flecainide Acetate [ep Impurity]
67. Flecainide Acetate [orange Book]
68. Flecainide Acetate [ep Monograph]
69. Flecainide Acetate [usp Impurity]
70. Ncgc00093934-01
71. Ncgc00093934-02
72. Ncgc00257762-01
73. As-11702
74. Flecainide Acetate [usp Monograph]
75. Hy-17429
76. Db-052497
77. Eu-0100546
78. Ft-0630667
79. En300-51344
80. D00638
81. E-0735
82. F 6777
83. 143f565
84. Sr-01000000172-2
85. Sr-01000000172-4
86. Sr-01000000172-5
87. Sr-01000000172-7
88. Q27089351
89. Flecainide Acetate, British Pharmacopoeia (bp) Reference Standard
90. Flecainide Acetate, European Pharmacopoeia (ep) Reference Standard
91. 2,5-bis(2,2,2-trifluoroethoxy)-n-(2-piperidylmethyl)benzamide Acetate
92. Flecainide Acetate, United States Pharmacopeia (usp) Reference Standard
93. 2-({[2,5-bis(2,2,2-trifluoroethoxy)benzoyl]amino}methyl)piperidinium Acetate
94. Flecainide For System Suitability, European Pharmacopoeia (ep) Reference Standard
Molecular Weight | 474.4 g/mol |
---|---|
Molecular Formula | C19H24F6N2O5 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 7 |
Exact Mass | 474.15894084 g/mol |
Monoisotopic Mass | 474.15894084 g/mol |
Topological Polar Surface Area | 96.9 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 531 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Flecainide acetate |
Drug Label | Flecainide acetate is an antiarrhythmic drug available in tablets of 50, 100, or 150 mg for oral administration. Flecainide acetate is benzamide, N-(2-piperidinylmethyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. Its molecular formula is C17H20F6N2... |
Active Ingredient | Flecainide acetate |
Dosage Form | Tablet |
Route | Oral |
Strength | 100mg; 50mg; 150mg |
Market Status | Prescription |
Company | Ranbaxy; Amneal Pharm; Roxane; Barr |
2 of 2 | |
---|---|
Drug Name | Flecainide acetate |
Drug Label | Flecainide acetate is an antiarrhythmic drug available in tablets of 50, 100, or 150 mg for oral administration. Flecainide acetate is benzamide, N-(2-piperidinylmethyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. Its molecular formula is C17H20F6N2... |
Active Ingredient | Flecainide acetate |
Dosage Form | Tablet |
Route | Oral |
Strength | 100mg; 50mg; 150mg |
Market Status | Prescription |
Company | Ranbaxy; Amneal Pharm; Roxane; Barr |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Voltage-Gated Sodium Channel Blockers
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15244
Submission : 2001-01-15
Status : Inactive
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-09-06
Pay. Date : 2022-07-01
DMF Number : 37212
Submission : 2022-06-20
Status : Active
Type : II
Certificate Number : CEP 2022-323 - Rev 00
Issue Date : 2024-12-19
Type : Chemical
Substance Number : 1324
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33666
Submission : 2019-03-29
Status : Active
Type : II
Certificate Number : CEP 2020-054 - Rev 02
Issue Date : 2024-05-30
Type : Chemical
Substance Number : 1324
Status : Valid
Date of Issue : 2021-08-06
Valid Till : 2024-03-04
Written Confirmation Number : WC-0294
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19272
Submission : 2006-03-23
Status : Active
Type : II
Certificate Number : R1-CEP 2009-289 - Rev 01
Issue Date : 2015-03-19
Type : Chemical
Substance Number : 1324
Status : Suspended by Holder
Date of Issue : 2024-04-23
Valid Till : 2027-04-22
Written Confirmation Number : WC-0170
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-02-07
Pay. Date : 2014-02-01
DMF Number : 23192
Submission : 2009-10-14
Status : Active
Type : II
Certificate Number : R1-CEP 2006-005 - Rev 02
Issue Date : 2020-08-13
Type : Chemical
Substance Number : 1324
Status : Suspended by Holder
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14749
Submission : 2000-02-29
Status : Active
Type : II
Certificate Number : CEP 2009-363 - Rev 03
Issue Date : 2023-12-06
Type : Chemical
Substance Number : 1324
Status : Valid
Registration Number : 223MF10093
Registrant's Address : VIALE DEL GHISALLO, 20 20151 MILAN ITALY
Initial Date of Registration : 2011-06-29
Latest Date of Registration : --
NDC Package Code : 17373-1283
Start Marketing Date : 2009-07-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-09-26
Pay. Date : 2023-08-29
DMF Number : 35760
Submission : 2021-03-31
Status : Active
Type : II
Certificate Number : CEP 2021-393 - Rev 00
Issue Date : 2024-06-10
Type : Chemical
Substance Number : 1324
Status : Valid
NDC Package Code : 72640-021
Start Marketing Date : 2021-03-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15244
Submission : 2001-01-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8849
Submission : 1990-08-10
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14749
Submission : 2000-02-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-07-13
Pay. Date : 2017-05-18
DMF Number : 31757
Submission : 2017-05-20
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-04-04
Pay. Date : 2014-02-05
DMF Number : 27859
Submission : 2014-01-28
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10688
Submission : 1994-01-24
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-09-22
Pay. Date : 2014-04-28
DMF Number : 28158
Submission : 2014-05-15
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24309
Submission : 2010-10-13
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33666
Submission : 2019-03-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19272
Submission : 2006-03-23
Status : Active
Type : II
Certificate Number : CEP 2009-363 - Rev 03
Status : Valid
Issue Date : 2023-12-06
Type : Chemical
Substance Number : 1324
Certificate Number : CEP 2017-183 - Rev 01
Status : Valid
Issue Date : 2023-12-13
Type : Chemical
Substance Number : 1324
Certificate Number : CEP 2021-410 - Rev 00
Status : Valid
Issue Date : 2024-03-11
Type : Chemical
Substance Number : 1324
Certificate Number : R0-CEP 2008-080 - Rev 01
Status : Withdrawn by Holder
Issue Date : 2011-06-01
Type : Chemical
Substance Number : 1324
Flecainide Acetate, Code 50970
Certificate Number : CEP 2013-145 - Rev 02
Status : Valid
Issue Date : 2023-12-05
Type : Chemical
Substance Number : 1324
Certificate Number : R1-CEP 2010-055 - Rev 03
Status : Withdrawn by Holder
Issue Date : 2022-04-01
Type : Chemical
Substance Number : 1324
Flecainide Acetate, Piramal Site
Certificate Number : R1-CEP 2017-106 - Rev 00
Status : Valid
Issue Date : 2022-10-28
Type : Chemical
Substance Number : 1324
Certificate Number : CEP 2020-054 - Rev 02
Status : Valid
Issue Date : 2024-05-30
Type : Chemical
Substance Number : 1324
Certificate Number : R1-CEP 2006-005 - Rev 02
Status : Suspended by Holder
Issue Date : 2020-08-13
Type : Chemical
Substance Number : 1324
Certificate Number : R1-CEP 2009-289 - Rev 01
Status : Suspended by Holder
Issue Date : 2015-03-19
Type : Chemical
Substance Number : 1324
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info : RX
Registration Country : USA
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Packaging :
Approval Date : 2002-10-28
Application Number : 75882
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Canada
Brand Name : APO-FLECAINIDE
Dosage Form : TABLET
Dosage Strength : 100MG
Packaging : 100
Approval Date :
Application Number : 2275546
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Italy
Brand Name : FLECAINIDE AUROBINDO
Dosage Form : Tablets 20 Tablets In Pvc/Pvdc/Al
Dosage Strength : 100 mg
Packaging : 20 UNITS 100 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info : RX
Registration Country : USA
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Packaging :
Approval Date : 2003-01-14
Application Number : 76278
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Tambocor CR 200
Dosage Form : CAP
Dosage Strength : 200mg
Packaging : 30X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info :
Registration Country : Sweden
Brand Name : Tambocor Retard
Dosage Form : PROLONGED-RELEASE CAPSULE, HARD
Dosage Strength : 200 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info : RX
Registration Country : USA
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Packaging :
Approval Date : 2003-03-28
Application Number : 76421
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Norway
Brand Name : Tambocor
Dosage Form : Tablet
Dosage Strength : 100 mg
Packaging : Blisterpakning 100item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Sweden
Brand Name : Tambocor
Dosage Form : TABLET
Dosage Strength : 100 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : Tambocor
Dosage Form : TABLET
Dosage Strength : 100 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
RLD : No
TE Code : AB
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 2001-07-31
Application Number : 75442
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 150MG
Approval Date : 2001-07-31
Application Number : 75442
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Approval Date : 2002-10-28
Application Number : 75882
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Approval Date : 2017-11-03
Application Number : 202821
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 2017-11-03
Application Number : 202821
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 150MG
Approval Date : 2009-07-09
Application Number : 79164
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Approval Date : 2003-01-14
Application Number : 76278
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 2003-01-14
Application Number : 76278
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 150MG
Approval Date : 2003-01-14
Application Number : 76278
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 2022-09-08
Application Number : 215599
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Flecainide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Flecainide, including repackagers and relabelers. The FDA regulates Flecainide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Flecainide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Flecainide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Flecainide supplier is an individual or a company that provides Flecainide active pharmaceutical ingredient (API) or Flecainide finished formulations upon request. The Flecainide suppliers may include Flecainide API manufacturers, exporters, distributors and traders.
click here to find a list of Flecainide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Flecainide DMF (Drug Master File) is a document detailing the whole manufacturing process of Flecainide active pharmaceutical ingredient (API) in detail. Different forms of Flecainide DMFs exist exist since differing nations have different regulations, such as Flecainide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Flecainide DMF submitted to regulatory agencies in the US is known as a USDMF. Flecainide USDMF includes data on Flecainide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Flecainide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Flecainide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Flecainide Drug Master File in Japan (Flecainide JDMF) empowers Flecainide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Flecainide JDMF during the approval evaluation for pharmaceutical products. At the time of Flecainide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Flecainide suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Flecainide Drug Master File in Korea (Flecainide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Flecainide. The MFDS reviews the Flecainide KDMF as part of the drug registration process and uses the information provided in the Flecainide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Flecainide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Flecainide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Flecainide suppliers with KDMF on PharmaCompass.
A Flecainide CEP of the European Pharmacopoeia monograph is often referred to as a Flecainide Certificate of Suitability (COS). The purpose of a Flecainide CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Flecainide EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Flecainide to their clients by showing that a Flecainide CEP has been issued for it. The manufacturer submits a Flecainide CEP (COS) as part of the market authorization procedure, and it takes on the role of a Flecainide CEP holder for the record. Additionally, the data presented in the Flecainide CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Flecainide DMF.
A Flecainide CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Flecainide CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Flecainide suppliers with CEP (COS) on PharmaCompass.
A Flecainide written confirmation (Flecainide WC) is an official document issued by a regulatory agency to a Flecainide manufacturer, verifying that the manufacturing facility of a Flecainide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Flecainide APIs or Flecainide finished pharmaceutical products to another nation, regulatory agencies frequently require a Flecainide WC (written confirmation) as part of the regulatory process.
click here to find a list of Flecainide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Flecainide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Flecainide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Flecainide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Flecainide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Flecainide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Flecainide suppliers with NDC on PharmaCompass.
Flecainide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Flecainide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Flecainide GMP manufacturer or Flecainide GMP API supplier for your needs.
A Flecainide CoA (Certificate of Analysis) is a formal document that attests to Flecainide's compliance with Flecainide specifications and serves as a tool for batch-level quality control.
Flecainide CoA mostly includes findings from lab analyses of a specific batch. For each Flecainide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Flecainide may be tested according to a variety of international standards, such as European Pharmacopoeia (Flecainide EP), Flecainide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Flecainide USP).
LOOKING FOR A SUPPLIER?